Close Menu

CHICAGO (GenomeWeb) – A PI3 kinase inhibitor called taselisib showed efficacy for the first time against patients with a solid tumor characterized by PIK3CA mutations.

And while the results of the trial weren't convincing enough for the drug's sponsor to continue to pursue US Food and Drug Administration approval, experts at the American Society of Clinical Oncology’s annual meeting this week said the data add to the field’s understanding of PIK3CA-mutated cancers and demonstrate that the PI3 kinase pathway is druggable in solid tumors.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.